Bridgefront Capital’s Sage Therapeutics SAGE Stock Holding History

Bridgefront Capital’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-8,044	Closed	-$457K	–	621
2021 Q2	$457K	Buy	+8,044	New	+$569K	0.17%	207

Other funds holding SAGE

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Bridgefront Capital's SAGE Position: Q3 2021 in Review

Bridgefront Capital sold out of Sage Therapeutics (SAGE) in Q3 2021, closing a stake of 8,044 shares — an estimated $457K sold.

Bridgefront Capital first reported a position in SAGE in Q2 2021 and held it in 1 quarter. The position peaked at $457K in Q2 2021. 225 funds tracked by Wall St. Rank hold SAGE as of Q3 2021.

Bridgefront Capital reported no remaining Sage Therapeutics position as of Q3 2021 after selling out during the quarter.
Bridgefront Capital sold 8,044 Sage Therapeutics shares in Q3 2021, an estimated $457K.
Bridgefront Capital first reported a position in Sage Therapeutics in Q2 2021 and held it in 1 quarter.
Bridgefront Capital's Sage Therapeutics position peaked at $457K in Q2 2021.
225 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2021.

Based on Bridgefront Capital's 13F filing for Q3 2021, filed 12 Nov 2021.